Journal article

Effect of 6 months hybrid closed-loop insulin delivery in young people with type 1 diabetes: a randomised controlled trial protocol

Martin de Bock, Sybil A McAuley, Mary Binsu Abraham, Grant Smith, Jennifer Nicholas, Geoff R Ambler, Fergus J Cameron, Jan M Fairchild, Bruce R King, Elizabeth A Geelhoed, Elizabeth A Davis, David Norman O'Neal, Timothy W Jones



INTRODUCTION: Automated insulin delivery (also known as closed loop, or artificial pancreas) has shown potential to improve glycaemic control and quality of life in people with type 1 diabetes (T1D). Automated insulin delivery devices incorporate an insulin pump with continuous glucose monitoring(CGM) and an algorithm, and adjust insulin in real time. This study aims to establish the safety and efficacy of a hybrid closed-loop (HCL) system in a long-term outpatient trial in people with T1D aged 12 -<25 years of age, and compare outcomes with standard therapy for T1D as used in the contemporary community. METHODS AND ANALYSIS: This is an open-label, multicentre, 6-month, randomised controlled..

View full abstract


Funding Acknowledgements

The study is supported by Juvenile Diabetes Research Foundation (JDRF) Australia, the recipient of the Australia Research Council Special Research Initiative in Type 1 Juvenile Diabetes. MDB was funded by Western Australia Department of Health and the Raine Medical Research Foundation, and the Australian Type 1 Diabetes Clinical Research Network initiative undertaken by the JDRF Australia supported by funding from the Australian Government Department of Health and Ageing. SAM is supported by a JDRF Early-Career Patient-Orientated Diabetes Research Award. Insulin pumps, transmitter and glucose sensors were provided by Medtronic via an unrestricted grant. MA was supported by JDRF Australia, the recipient of the Australian Research Council Special Research Initiative in Type 1 Juvenile Diabetes.